|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Therapeutics and Diagnostics for Women's Disorders
|
Mar 2009 |
£3,065 |
100% |
|
New Therapeutics and Diagnostics for Women’s Disorders
|
May 2005 |
£2,760 |
88% |
|
ADHD Therapeutics
|
Jun 2010 |
£2,500 |
73% |
|
Pharmaceutical Regulatory Industry
|
Jan 2006 |
£2,760 |
72% |
|
Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets
|
Jul 2010 |
£3,065 |
68% |
Stakeholder Opinions: Parkinson\'s Disease
Review of Key Commercial Opportunities in the Symptomatic Treatment Market
|
Jul 2006 |
£1,335 |
66% |
Personalized Medicine (2 parts)
Technologies, Markets and Companies
|
Jan 2012 |
£3,240 |
66% |
Irritable Bowel Syndrome (IBS) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Sep 2011 |
£2,215 |
64% |
Biobanking: Ownership
A Global Market Watch, 2009-2015
|
Nov 2011 |
£1,840 |
64% |
|
Pediatric Health Care Products and Services
|
Mar 2009 |
£3,065 |
63% |
Biorepositories: Technologies & Ownership
A Global Market Watch, 2009-2015
|
Nov 2011 |
£2,810 |
62% |
Biorepositories: Ownership & End-users
A Global Market Watch, 2009-2015
|
Nov 2011 |
£2,070 |
62% |
Biorepositories: Applications & Ownership
A Global Market Watch, 2009-2015
|
Nov 2011 |
£2,635 |
62% |
|
Patient Monitoring Markets
|
Oct 2009 |
£2,150 |
61% |
Biorepositories: Equipments & Ownership
A Global Market Watch, 2009-2015
|
Nov 2011 |
£2,980 |
60% |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
Jun 2007 |
£2,405 |
60% |
|
GE Healthcare Medical Device Company Intelligence Report
|
Feb 2011 |
£495 |
60% |
|
Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
|
Mar 2009 |
£1,265 |
60% |
|
Irritable Bowel Syndrome (IBS) Therapeutics
|
Aug 2011 |
£2,845 |
58% |
Biorepositories: Equipments, Applications, Technologies, Ownership and End-users
An Analytical Report, 2009-2015
|
Nov 2011 |
£4,175 |
56% |
|
Spinal Surgery
|
Oct 2011 |
£2,845 |
55% |
|
Monoclonal Antibody Based Products
|
Oct 2008 |
£2,500 |
54% |
|
Cardiovascular Catheters and Systems
|
Apr 2008 |
£2,500 |
53% |
|
Bard Medical Device Company Intelligence Report
|
Aug 2011 |
£295 |
49% |
Commercial Insight: Osteoporosis
Market players maximize revenue growth before the next challenging phase
|
Jul 2010 |
£9,615 |
48% |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
Dec 2006 |
£2,400 |
47% |
